Page 10 - Core One News Today

Plant-Based Investment Corp.: PBIC To Rescind Share Exchange With Core One Labs Company") ( Core One") to rescind the share exchange transaction previously completed between the parties (the " Share Exchange"). Effective March 16, 2020, the Company subscribed for and acquired 5,333,333 common shares of Core One (or 2,666,667 common shares of Core One after giving effect to Core Ones share consolidation completed on July 8, 2020), and in consideration issued 3,149,606 common shares of PBIC to Co...

Press release content from Accesswire. The AP news staff was not involved in its creation. Core One Labs to Rescind Share Exchange with Plant-Based Investment Corp. April 15, 2021 GMT VANCOUVER, BC / ACCESSWIRE / April 14, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(FRA:LD62)(WKN:A2P8K3) (the "Company" or "Core One") announces that it has reached an agreement with Plant-Based Investment Corp. (formerly, Cannabis Growth ... VANCOUVER, BC / ACCESSWIRE / April 14, 2021 / Core One Labs Inc...

Core One Labs Inc.: Core One Labs Vocan Expands Product Commercialization Team Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the " Company" or " Core One") is pleased to announce its wholly-owned subsidiary Vocan Biotechnologies Inc. (" Vocan") has expanded its product commercialization team, adding Dr. Elizabeth Matthews as Head of Scientific and Regulatory Affairs. Dr. Matthews will oversee research and development, as well as the commercialization of Vocans new...

Core One Labs Inc.: Core One Labs Initiates First Strain Production for Biosynthetic Psilocybin VANCOUVER, BC / ACCESSWIRE / February 26, 2021 / Core One Labs Inc. (CSE:COOL), (OTC PINK:CLABF), (Frankfurt:LD62, WKN: A2P8K3) (the "Company" or "Core One") a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce readiness to begin initial biosynthetic psilocybin production trials. The Companys wholly owned subsid...

VANCOUVER, BC / ACCESSWIRE / February 24, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62)(WKN:A2P8K3) (the "Company" or "Core One") a research and technology company focused in life

Core One Labs Inc.: Core One Labs Highlights Key Points from International Investor Call Core One" the " Company") is pleased with the tremendous turnout on the International Investors Call held earlier today. Core Ones Chairman, Dr. Robert E.W. Hancock and Chief Executive Officer, Joel Shacker provided participants an update on the Companys current Intellectual Property and patent application process, cost to produce psilocybin, and the commercial viability. Highlights Intellectual Property an...

Press release content from Accesswire. The AP news staff was not involved in its creation. Core One Labs Highlights Key Points from International Investor Call February 11, 2021 GMT VANCOUVER, BC / ACCESSWIRE / February 10, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (“Core One” the “Company”) is pleased with the tremendous turnout on the International Investors’ Call held earlier today. Core One’s Chairman, Dr. Robert E.W. Hancock and Chief Ex...

Press release content from Accesswire. The AP news staff was not involved in its creation.

(6) VANCOUVER, BC / ACCESSWIRE / February 6, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62)(WKN:A2P8K3) (the "Company") announces that it has engaged Donohoe Advisory Associates LLC ("Donohoe Advisory") in connection with its efforts to seek a listing for its common shares on a NASDAQ Stock Market. The Company expects that listing its common shares on NASDAQ will provide increased investor awareness and market liquidity for shareholders. Donohoe Advisory was founded by Dav...

Core One Labs Inc.: Core One Labs Announces Its Entrance into the Ketamine Space with Proposed Acquisition of Ketamine Infusion Centers of Texas Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the " Company") a biotechnology research and development company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy is pleased to announce it has entered into a letter of intent (the " ...